This site is intended for qualified researchers aged 21 or older.
CJC-1295 (No DAC) and Ipamorelin are combined to activate complementary growth hormone pathways. CJC-1295 is a modified GRF analog acting at the GHRH receptor. Ipamorelin is a selective ghrelin receptor agonist with no measured effect on cortisol or prolactin in research settings. Each vial is lyophilized at a 1:1 ratio by weight, sealed, and shipped with a lot-specific Certificate of Analysis.